Ardelyx appoints Paul Korner as Executive Vice President and Chief Medical Officer

He beings extensive experience to the newly created role

Ardelyx, a California, US-based biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, has appointed Paul Korner to the newly created position of Executive Vice President and Chief Medical Officer.

Dr Korner brings extensive medical affairs and clinical development experience to the firm.

For 17 years, he has held various leadership positions with several global pharmaceutical companies. Over the past seven years, he has been President, Ferring International Pharmascience Centre US (FIPCUS) & Senior Vice President, US Development for Ferring Pharmaceuticals, where he built and led Ferring's US clinical development subsidiary responsible for gastroenterology, reproductive health, orthopaedics and urology therapeutic areas and was a member of senior global R&D management.

Dr Korner joined Ferring in 2008 as Vice President, Medical Affairs, responsible for pharmacovigilance, medical information and medical staff supporting Ferring's marketed products.

Prior to joining Ferring, Dr Korner was Vice President of Medical Affairs, Female Health at Bayer HealthCare Pharmaceuticals. He was also Senior Director of Clinical Research and Development, Women's Health and Musculoskeletal Bone Repair for Wyeth Research and as Director, Medical Affairs – GI and Women's Health for Solvay Pharmaceuticals.

You may also like